Residency · Residency · Cardiothoracic Surgery
Lung Transplant: Indications, Technique, and Outcomes
Introduction
Lung transplantation is the definitive treatment for select patients with end-stage lung disease refractory to medical therapy. Over 4,500 lung transplants are performed annually worldwide, with improvements in donor management, surgical technique, and postoperative care yielding progressive gains in survival. The cardiothoracic surgeon must understand disease-specific considerations, operative strategy, and management of early and late complications.
Indications and Disease-Specific Considerations
General Criteria
Candidates for lung transplantation have end-stage lung disease with high risk of death within 2 years without transplant, have failed maximal medical therapy, and are evaluated using the Lung Allocation Score (LAS), which incorporates severity of illness and expected post-transplant survival. Patients should be ambulatory with rehabilitation potential and adequate nutritional status, and should have no active malignancy, uncontrolled infection, or significant extrapulmonary organ dysfunction.
Disease-Specific Indications
COPD and emphysema patients are considered when FEV1 falls below 20% predicted, the BODE index reaches 7-10, or frequent severe exacerbations occur. Idiopathic pulmonary fibrosis (IPF) candidates demonstrate a decline in FVC exceeding 10% over 6 months, DLCO below 40%, or oxygen requirement at rest. Cystic fibrosis patients with FEV1 below 30% predicted, rapid decline, frequent hospitalizations, and resistant infections require bilateral transplant. Pulmonary arterial hypertension patients in NYHA class III-IV despite maximal medical therapy with a cardiac index below 2 L/min/m2 are also candidates. Alpha-1 antitrypsin deficiency patients with severe emphysema meeting COPD criteria qualify as well.
Single vs. Bilateral Transplant
Bilateral lung transplant is preferred for most indications and is mandatory for suppurative diseases such as cystic fibrosis and bronchiectasis to prevent infection of the allograft from the native lung. Single lung transplant is acceptable for IPF and COPD in select patients, offering shorter operative time and reduced donor utilization. Bilateral transplant offers superior long-term survival and functional outcomes in most disease categories.
Disease-Specific Indications and Transplant Type
| Disease | Referral Criteria | Transplant Type | Special Considerations |
|---|---|---|---|
| COPD / Emphysema | FEV1 < 20%; BODE 7-10; frequent exacerbations | Single or bilateral | Bilateral preferred for better long-term outcomes |
| Idiopathic Pulmonary Fibrosis (IPF) | FVC decline > 10% over 6 months; DLCO < 40%; resting O2 need | Single or bilateral | Rapid progression common; early referral essential |
| Cystic Fibrosis | FEV1 < 30%; rapid decline; resistant infections | Bilateral (mandatory) | Suppurative disease; native lung would infect allograft |
| Pulmonary Arterial Hypertension | NYHA III-IV; CI < 2 L/min/m2 despite maximal therapy | Bilateral | Requires intraoperative ECMO/CPB support |
| Alpha-1 Antitrypsin Deficiency | Severe emphysema meeting COPD criteria | Single or bilateral | Younger patients; bilateral preferred |
Donor Selection and Procurement
Ideal Donor Criteria
Ideal lung donors are younger than 55 years with a PaO2/FiO2 ratio above 300 on FiO2 1.0 and PEEP 5, a clear chest radiograph without infiltrates, clean bronchoscopy without purulent secretions or aspiration, no significant smoking history (less than 20 pack-years), and absence of chest trauma or pulmonary contusion.
Extended Criteria and Ex-Vivo Lung Perfusion (EVLP)
Extended criteria donors are increasingly used to expand the donor pool. EVLP allows lungs initially deemed unsuitable to be perfused ex-vivo at normothermic conditions for 4-6 hours. Assessment during EVLP includes delta PO2, compliance, pulmonary vascular resistance, and chest X-ray appearance. EVLP can rehabilitate donor lungs, increasing transplant rates by 15-20%.
Procurement Technique
Procurement involves antegrade flush with cold low-potassium dextran solution (Perfadex) via the pulmonary artery, followed by retrograde flush via pulmonary veins. The lungs are inflated to moderate volume (FiO2 0.5, CPAP 5-7 cmH2O) for transport and placed in cold static storage at 4 degrees C, with an ideal ischemic time of less than 6-8 hours.
Surgical Technique
Bilateral Sequential Lung Transplant
The approach uses a clamshell incision (bilateral anterior thoracotomy through the 4th intercostal space with transverse sternotomy) or bilateral anterolateral thoracotomies. The operation begins with the worse-functioning lung as assessed by perfusion scan. Pneumonectomy involves dividing the pulmonary artery, pulmonary veins, and bronchus of the native lung.
The implantation sequence proceeds as follows. The bronchial anastomosis is performed end-to-end with running or interrupted absorbable suture, using a telescoping technique to reduce ischemic complications. The pulmonary artery anastomosis uses continuous polypropylene suture. The left atrial cuff (pulmonary veins) anastomosis is completed with continuous polypropylene suture. Reperfusion is performed gradually to reduce ischemia-reperfusion injury by avoiding abrupt high-flow reperfusion. The entire process is then repeated for the contralateral side.
Cardiopulmonary Bypass / ECMO Support
CPB or ECMO is not routinely required for all bilateral lung transplants but is indicated for pulmonary hypertension, hemodynamic instability during single-lung ventilation, or severe hypoxemia. Intraoperative VA ECMO is increasingly preferred over full CPB due to reduced anticoagulation requirements and inflammatory response. Some centers transition intraoperative ECMO to postoperative VV ECMO support prophylactically.
Early Postoperative Care
Primary Graft Dysfunction (PGD)
PGD is the leading cause of early mortality and occurs within 72 hours. The ISHLT PGD Grading system classifies it as Grade 0 (PaO2/FiO2 above 300 with clear CXR), Grade 1 (PaO2/FiO2 above 300 with infiltrates), Grade 2 (PaO2/FiO2 200-300), and Grade 3 (PaO2/FiO2 below 200). Management includes lung-protective ventilation, diuresis, inhaled nitric oxide, and prone positioning. Severe PGD (Grade 3) warrants consideration of VV ECMO support.
| ISHLT PGD Grade | PaO2/FiO2 Ratio | Chest Radiograph | Management |
|---|---|---|---|
| Grade 0 | > 300 | Clear | Standard postoperative care |
| Grade 1 | > 300 | Infiltrates present | Lung-protective ventilation; diuresis |
| Grade 2 | 200-300 | Any | Inhaled NO; diuresis; optimize ventilation |
| Grade 3 | < 200 | Any | VV ECMO consideration; prone positioning; inhaled NO |
Ventilator Management
A lung-protective strategy is employed with tidal volume of 6-8 mL/kg ideal body weight, PEEP of 5-8 cmH2O, and FiO2 titrated to PaO2 above 60. Early extubation within 24-48 hours is pursued when feasible, and care is taken to avoid barotrauma at the bronchial anastomosis.
Immunosuppression
Induction uses basiliximab or ATG. Maintenance consists of triple therapy with tacrolimus, mycophenolate mofetil, and prednisone. Aggressive infection prophylaxis includes antimicrobials tailored to donor and recipient cultures, antifungal prophylaxis, and CMV prophylaxis.
Long-Term Complications
Chronic Lung Allograft Dysfunction (CLAD)
CLAD is the leading cause of late mortality, affecting 50% of recipients by 5 years. Bronchiolitis obliterans syndrome (BOS) represents the obstructive phenotype with progressive decline in FEV1. Restrictive allograft syndrome (RAS) is the restrictive phenotype with a worse prognosis than BOS. Management includes augmented immunosuppression, azithromycin for its anti-inflammatory properties, and photopheresis, with retransplantation considered in select cases.
Other Late Complications
Airway complications including bronchial stenosis and dehiscence occur in 2-10% of cases. Infections from bacterial pneumonia, CMV, and aspergillus are ongoing risks. Malignancy, particularly post-transplant lymphoproliferative disorder (PTLD) and skin cancers, requires surveillance. Renal dysfunction from calcineurin inhibitor toxicity affects long-term outcomes.
Outcomes
Median survival is approximately 6.5 years for bilateral and 4.5 years for single lung transplant. One-year survival reaches 85-90% at experienced centers, while 5-year survival is 55-60%. Quality of life and functional capacity are significantly improved post-transplant.
Key Clinical Pearls
Bilateral lung transplant is preferred for most indications and is mandatory for suppurative lung diseases. EVLP is a transformative technology allowing rehabilitation of marginal donor lungs and expansion of the donor pool. Primary graft dysfunction Grade 3 is the leading early killer, and VV ECMO is the rescue strategy. Chronic lung allograft dysfunction (CLAD) remains the Achilles heel of lung transplantation, with no definitive treatment. The bronchial anastomosis is the most vulnerable site due to lack of direct bronchial arterial blood supply post-transplant.
References
- Chambers DC, Perch M, Zuckermann A, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-eighth adult lung transplantation report. J Heart Lung Transplant. 2021;40(10):1173-1186.
- Cypel M, Yeung JC, Liu M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med. 2011;364(15):1431-1440.
- Snell GI, Yusen RD, Weill D, et al. Report of the ISHLT working group on primary lung graft dysfunction: definition and grading. J Heart Lung Transplant. 2017;36(10):1097-1103.
- Verleden GM, Glanville AR, Lease ED, et al. Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment. J Heart Lung Transplant. 2019;38(5):493-503.